Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease

Nowell, Joseph; Blunt, Eleanor; Gupta, Dhruv Sanjay; Edison, Paul

doi:10.1016/j.arr.2023.101979

Cited by 37 publications

(20 citation statements)

References 243 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Drug repurposing is a new international plan empowered by international linked clinical trials to explore the potential of non-anti-Parkinsonian validated medications for PD [ 102 , 103 , 104 ]. Although an old antidiabetic drug, exenatide (long acting glucagon-like peptide-1 (GLP-1) receptor agonist) may deploy neuroprotective and anti-neurotoxic action both in PD mice models [ 105 , 106 , 107 ] and PD patients with a constant motor and cognitive improvement over a 12 month-follow up [ 108 ].…”

Section: Resultsmentioning

confidence: 99%

Some Novel Therapies in Parkinson’s Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature

Bougea

2024

Biomedicines

View full text Add to dashboard Cite

In light of the unsuccessful traditional therapies for Parkinson’s disease (PD) overmany years, there is an unmet need for the development of novel therapies to alleviate the symptoms of PD retardation or halt the progression of the disease itself. This systematic review aims to critically update some of the most promising novel treatments including gene therapy, cell-based therapies, targeted drug delivery, and neuroprotective agents, focusing on their challenges, limitations and future directions in PD research. Gene therapy in PD is encouraging, with AAV-based approaches targeting neurotrophic factors, dopamine production, and neuronal circuits in animal and clinical trials. A promising approach to targeted drug delivery for PD involves the use of nanotechnology to create drug delivery vehicles that can traverse the blood–brain barrier and deliver medications specifically to the regions of the brain affected by PD. Neuroprotective agents are compounds that have the ability to protect neurons from degeneration and death, and they hold great promise for the evolution of disease-modifying treatments for PD. Magnetic field therapy is a promising non-invasive method that promotes neural plasticity in PD. The establishment of standardized protocols for animal and human studies, safety, ethical considerations, and cost-effectiveness are the major challenges for the future research of novel PD therapies. The development of novel therapies for PD represents a promising path toward to effective personalized disease-modifying treatments for PD.

show abstract

Section: Resultsmentioning

confidence: 99%

Some Novel Therapies in Parkinson’s Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature

Bougea

2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Furthermore, these GLP-1RA medications have also been related to a reduction of neuroinflammation, probably due to its possible role in neuronal insulin signaling pathway restoration ( 49 , 67 , 68 ). Hence, semaglutide and liraglutide could also have the potential to ameliorate neurodegeneration processes observed in pathologies like Alzheimer’s and Parkinson’s diseases, although further research is needed ( 48 , 69 ). Moreover, clinical trials have reported a reduction of the inflammatory C-reactive protein ( 70 ), which could indicate that this drug may also regulate the immune system, although this approach requires further assessment.…”

Section: Discussionmentioning

confidence: 99%

Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity

Tamayo-Trujillo,

Ruiz-Pozo,

Cadena-Ullauri

et al. 2024

Front. Nutr.

View full text Add to dashboard Cite

Obesity, a chronic global health problem, is associated with an increase in various comorbidities, such as cardiovascular disease, type 2 diabetes mellitus, hypertension, and certain types of cancer. The increasing global prevalence of obesity requires research into new therapeutic strategies. Glucagon-like peptide-1 receptor agonists, specifically semaglutide and liraglutide, designed for type 2 diabetes mellitus treatment, have been explored as drugs for the treatment of obesity. This minireview describes the molecular mechanisms of semaglutide and liraglutide in different metabolic pathways, and its mechanism of action in processes such as appetite regulation, insulin secretion, glucose homeostasis, energy expenditure, and lipid metabolism. Finally, several clinical trial outcomes are described to show the safety and efficacy of these drugs in obesity management.

show abstract

“… 13 , 14 GLP-1 RAs, including semaglutide, may mitigate AD and PD risk through various mechanisms, although current evidence on cognitive benefits is inconclusive, with mixed results from trials involving liraglutide and exenatide. 15 Additionally, meta-analyses suggest potential benefits of GLP-1 RAs, particularly exenatide, on motor symptoms in PD, with low-certainty evidence indicating improvements in cognition. 15 …”

Section: Glp-1 Agonists In Psychiatric Disordersmentioning

confidence: 99%

“… 15 Additionally, meta-analyses suggest potential benefits of GLP-1 RAs, particularly exenatide, on motor symptoms in PD, with low-certainty evidence indicating improvements in cognition. 15 …”

Section: Glp-1 Agonists In Psychiatric Disordersmentioning

confidence: 99%

The Potential Role of GLP-1 Agonists in Psychiatric Disorders: A Paradigm Shift in Mental Health Treatment

Gunturu

2024

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease

Cited by 37 publications

References 243 publications

Some Novel Therapies in Parkinson’s Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature

Some Novel Therapies in Parkinson’s Disease: A Promising Path Forward or Not Yet? A Systematic Review of the Literature

Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity

The Potential Role of GLP-1 Agonists in Psychiatric Disorders: A Paradigm Shift in Mental Health Treatment

Contact Info

Product

Resources

About